CN111053798A - 一种富含愉悦激素前体的葵花籽组合物及抗抑郁应用 - Google Patents
一种富含愉悦激素前体的葵花籽组合物及抗抑郁应用 Download PDFInfo
- Publication number
- CN111053798A CN111053798A CN202010005574.3A CN202010005574A CN111053798A CN 111053798 A CN111053798 A CN 111053798A CN 202010005574 A CN202010005574 A CN 202010005574A CN 111053798 A CN111053798 A CN 111053798A
- Authority
- CN
- China
- Prior art keywords
- sunflower
- sunflower seed
- sunflower seeds
- composition
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000020238 sunflower seed Nutrition 0.000 title claims abstract description 98
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 239000002243 precursor Substances 0.000 title abstract description 6
- 229940088597 hormone Drugs 0.000 title abstract description 4
- 239000005556 hormone Substances 0.000 title abstract description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 21
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 20
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims abstract description 17
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims abstract description 17
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims abstract description 17
- 229940074393 chlorogenic acid Drugs 0.000 claims abstract description 17
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims abstract description 17
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims abstract description 17
- 235000001368 chlorogenic acid Nutrition 0.000 claims abstract description 17
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims abstract description 17
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 13
- 229940012843 omega-3 fatty acid Drugs 0.000 claims abstract description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 11
- 239000008103 glucose Substances 0.000 claims abstract description 11
- 229940088594 vitamin Drugs 0.000 claims abstract description 11
- 229930003231 vitamin Natural products 0.000 claims abstract description 11
- 235000013343 vitamin Nutrition 0.000 claims abstract description 11
- 239000011782 vitamin Substances 0.000 claims abstract description 11
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims abstract description 7
- 238000005238 degreasing Methods 0.000 claims abstract description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000003921 oil Substances 0.000 claims description 14
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 9
- 229960000304 folic acid Drugs 0.000 claims description 9
- 235000019152 folic acid Nutrition 0.000 claims description 9
- 239000011724 folic acid Substances 0.000 claims description 9
- 230000036651 mood Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000011715 vitamin B12 Substances 0.000 claims description 8
- 239000011726 vitamin B6 Substances 0.000 claims description 8
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 7
- 239000006014 omega-3 oil Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 230000003001 depressive effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000002137 ultrasound extraction Methods 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 239000011691 vitamin B1 Substances 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 238000009098 adjuvant therapy Methods 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 239000011716 vitamin B2 Substances 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims 2
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 41
- 230000000694 effects Effects 0.000 abstract description 28
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract description 20
- 210000004556 brain Anatomy 0.000 abstract description 10
- 229960003638 dopamine Drugs 0.000 abstract description 10
- 239000002858 neurotransmitter agent Substances 0.000 abstract description 9
- 229940076279 serotonin Drugs 0.000 abstract description 8
- 238000000605 extraction Methods 0.000 abstract description 7
- 150000001413 amino acids Chemical class 0.000 abstract description 4
- 230000001430 anti-depressive effect Effects 0.000 abstract description 3
- 229930014626 natural product Natural products 0.000 abstract description 3
- 230000007935 neutral effect Effects 0.000 abstract description 3
- 230000002641 glycemic effect Effects 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 102000007544 Whey Proteins Human genes 0.000 description 12
- 108010046377 Whey Proteins Proteins 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 235000021119 whey protein Nutrition 0.000 description 12
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 11
- 229960002748 norepinephrine Drugs 0.000 description 11
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 208000019901 Anxiety disease Diseases 0.000 description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 230000009182 swimming Effects 0.000 description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000000971 hippocampal effect Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 208000007415 Anhedonia Diseases 0.000 description 4
- 206010012374 Depressed mood Diseases 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 108010073771 Soybean Proteins Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 235000007215 black sesame Nutrition 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 235000019710 soybean protein Nutrition 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 230000008925 spontaneous activity Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000207961 Sesamum Species 0.000 description 2
- 235000003434 Sesamum indicum Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 229940000252 folic acid 2 mg Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000012346 open field test Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 235000020927 12-h fasting Nutrition 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101000954509 Trichosurus vulpecula Very early lactation protein Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 230000006400 anxiety behaviour Effects 0.000 description 1
- 230000007529 anxiety like behavior Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000007357 depressive behavior Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000020828 fasting Nutrition 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种富含愉悦激素前体的葵花籽组合物及抗抑郁应用,属于天然产物提取及应用领域。本发明提供的组合物所用葵花籽富含色氨酸,且色氨酸/中性氨基酸比例高,经过脱脂和脱绿原酸处理,添加部分能够升高血糖指数,促进色氨酸吸收转化的葡萄糖和维生素,以及利于神经活动的ω‑3脂肪酸,促进葵花籽能更好的发挥抗抑郁功效。本发明的葵花籽组合物能够提高脑内单胺类神经递质血清素和多巴胺的浓度,对抑郁有很好的改善和治疗功效。本组合物采用天然葵花籽为原料,抗抑郁效果明显、来源丰富且无副作用。
Description
技术领域
本发明涉及一种富含愉悦激素前体的葵花籽组合物及抗抑郁应用,属于天然产物提取及应用领域。
背景技术
抑郁症是一种情绪、睡眠、食欲、兴趣、思考力普遍紊乱的情感性精神疾病,其致病率、***率、致残率和死亡率都极高,且反复发作,不易治愈,不仅给患者造成了极大的困扰和折磨,也给家庭和社会造成了巨大的经济损失。研究发现女性群体比男性更易出现情绪低落,其抑郁情绪的发生率是男性的3倍左右。在当今生活快节奏和高强度的压力下,抑郁症发病率逐年上升,世界卫生组织估计到2020年抑其将成为仅次于心脏病的第二大疾患。目前的许多合成抗抑郁药物仍存在起效缓慢、长期服用副作用大、低反应率等不足。如今,抑郁症治疗的新趋势是针对使用具有更好反应率和更少副作用的天然产品。
大脑产生的5-羟色胺参与情绪调节(图1),其前体为色氨酸。血液游离色氨酸通过活跃的蛋白质穿梭体穿过血脑屏障进入大脑,其他五种大型中性氨基酸(LNAAs:缬氨酸、亮氨酸、异亮氨酸、苯丙氨酸、酪氨酸)也参与竞争,Trp与其他LNAAs的比值(TRP/RLNAA比值)被认为是脑色氨酸更敏感的可用性指标这个比例决定了色氨酸能进入大脑的程度,比值越大,Trp更具竞争力,越易进入大脑发挥作用。抑郁症的一个常见原因就是患者体内血糖水平控制不平衡,血糖控制受损就会出现头晕、疲劳、易怒、抑郁等症状,表现为对胰岛素敏感性降低。补充适当葡萄糖可以诱导个体血液中胰岛素水平升高,色氨酸/中性氨基酸(LNAA)水平随胰岛素水平升高而升高,有利于色氨酸的吸收。维生素在控制神经递质产生和平衡的关键酶中起辅助作用,B族维生素如B6、B12、叶酸是人体内部辅酶的组成成分,与氨基酸代谢密切相关。如5-HTP转化为5-HT过程中所需的甲基羧化酶合成就高度依赖于B族维生素;色氨酸转化为血清素,苯丙氨酸转化为酪氨酸,酪氨酸再转化为多巴胺、去甲肾上腺素和肾上腺素等都需要B6、B12、叶酸等维生素,以此来促进愉悦性神经递质的吸收转化。增加ω-3脂肪酸饮食摄入能增加中枢5-HT活性,从而改善抑郁症,当脑内没有足够ω-3脂肪酸时,就难以识别5-HT信号,激活不了脑细胞,导致整个大脑失去5-HT功能,增加个体对抑郁症发病诱因的易感性。ω-3脂肪酸也能通过改变细胞膜的流动性和作为炎性细胞因子及类花生酸类物质的前体而影响神经传过程,可能与抗抑郁效应有关。补充ω-3脂肪酸的人更不容易抑郁,这就像在工厂里建造更多的血清素,而不是仅仅增加你现有的血清素的利用率,从而提高5-HT的生成效率和吸收率。
乳清蛋白、葵花籽和黑芝麻蛋白是富含色氨酸和酪氨酸的蛋白,但是我国乳清蛋白分离技术起步晚,目前尚没有具有自主知识产权的乳清蛋白综合利用技术,而国外技术受专利保护,因而我国的乳清蛋白等资源主要依赖于进口;我国黑芝麻种植历史悠久,芝麻蛋白营养价值高,其蛋白质氨基酸除赖氨酸含量低外,其余与牛肉或酪蛋白相比,接近或达到FAO/WHO建议优质蛋白,但是存在黑芝麻蛋白产量较低,加工规模、商品转化率较低,制油过程中易存在蛋白质变性问题,直接影响蛋白质利用价值和功能性,造成蛋白质的浪费,而且黑芝麻中存在过敏原,颜色会影响色泽等问题;此外,芝麻含有的水溶性氮(NSI)限制其利用范围。
发明内容
本发明的第一个目的在于提供葵花籽或含葵花籽的组合物在辅助治疗、缓解或改善抑郁情绪,或制备治疗抑郁症的药物中的应用;所述葵花籽满足:色氨酸含量≥1.0g/100g葵花籽蛋白的要求。
在一种实施方式中,所述药物含有葵花籽蛋白和药学上可接受的载体。
在一种实施方式中,所述组合物中含有葵花籽30-500g,葡萄糖25~150mg,ω-3脂肪酸200-1000mg和复合维生素。
在一种实施方式中,所述复合维生素包括维生素A、维生素B1,维生素B2,维生素B6,维生素B12和叶酸。
在一种实施方式中,所述组合物中含有葵花籽30-500g,维生素B6 5~50mg,葡萄糖25~150mg,叶酸0.4~2mg,维生素B12 5-50μg,ω-3脂肪酸200-1000mg。
在一种实施方式中,所述组合物含有葵花籽粉367g(提供蛋白140g),玉米淀粉439.4g,微晶纤维素31.7g,胆碱2.3g,ω-3脂肪酸0.5g,维生素A8mg、维生素B1 6mg、维生素B2 6mg、维生素B6 7mg、维生素B12 10ug和叶酸2mg。
在一种实施方式中,所述葵花籽的色氨酸含量为1.0-3.0g/100g葵花籽蛋白。
在一种实施方式中,所述葵花籽蛋白是将葵花籽先后经过脱脂、脱绿原酸处理后获得的蛋白质。
在一种实施方式中,所述脱脂处理是经榨油机脱油至油脂含量低于24%。
在一种实施方式中,所述脱绿原酸的过程是:将葵花籽置于体积分数50%-60%的乙醇中,料液比1:10-1:14,于35-50℃下超声提取25-35min,超声功率140-160W,真空抽滤,而后将产品进行真空干燥。
在一种实施方式中,所述葵花籽的摄入量≥1.5g葵花籽/kg体重。
在一种实施方式中,所述葵花籽组合物的摄入量≥3g葵花籽组合物/kg体重。
本发明的第二个目的是提供一种组合物,含有葵花籽30-500g,维生素B6 5~50mg,葡萄糖25~150mg,叶酸0.4~2mg,维生素B12 5-50μg,ω-3脂肪酸200-1000mg;所述葵花籽满足:色氨酸含量≥1.0g/100g蛋白的要求。
本发明还要求保护所述葵花籽组合物的制备方法,是将葵花籽经脱脂、脱绿原酸处理,再与维生素B6 5~50mg,葡萄糖25~150mg,叶酸0.4~2mg,维生素B12 5-50μg,ω-3脂肪酸200-1000mg混合。
本发明还要求保护葵花籽蛋白在制备预防、治疗、缓解或改善抑郁情绪的食品、药品或保健品中的应用;所述葵花籽蛋白满足:色氨酸含量≥1.0g/100g葵花籽蛋白的要求。
有益效果:本发明选取富含色氨酸、苯丙氨酸和酪氨酸的葵花籽,与葡萄糖、色氨酸、维生素B6、维生素B12、叶酸等维生素等组分配合,能够促进色氨酸转化为血清素,苯丙氨酸转化为酪氨酸,酪氨酸再转化为多巴胺、去甲肾上腺素和肾上腺素,促进愉悦性神经递质的吸收转化。本发明通过动物实验证实喂食葵花籽可使小鼠对糖水偏好率提高18.1%~25.4%,在悬尾实验和强迫游泳实验中静止时间分别减少28.2~40.5%,32.6~35.3%。对海马神经递质含量的测定结果显示,喂食葵花籽可使血清素(5-HT)和去甲肾上腺素(NE)分别提高22.61%~36.68%,和10.64%~70.48%,可缓解小鼠快感缺失状态,增加快感,有效缓解小鼠抑郁焦虑情绪。
附图说明
图1为5-羟色胺参与情绪调节的关系;
图2为葵花籽对小鼠体重变化的影响;结果为平均值±标准偏差,p<0.05;
图3为葵花籽对小鼠糖水偏好率的影响;结果为平均值±标准偏差,p<0.05;
图4为葵花籽对小鼠悬尾实验结果;(a)和强迫游泳实验(b)活动的影响;结果为平均值±标准偏差,p<0.05;
图5为葵花籽对小鼠海马神经递质的影响;(a)海马组织中血清素(5-HT)含量;(b)海马多巴胺(DA)含量;(c)去甲肾上腺素(NE)含量;结果为平均值±标准偏差,p<0.05。
具体实施方式
油脂含量的检测方法:采用全自动脂肪测定仪VELP分析葵花籽油脂含量,精确称取5g样品于萃取滤纸筒内,在抽提杯中加入100mL石油醚,经Immersion(60min)、Removing(10min)、Washing(60min)、Recovery(30min)、Cooling(3min)全自动分析过程测定油脂含量。
绿原酸检测方法:准确称取粉碎后葵花籽2.0g,按照料液比1:13,加入体积分数为60%乙醇溶液,温度40℃,放入超声波清洗器中,调节超声功率为150W,超声浸提30min,离心取上清液1mL,定容至100mL,待测。准确称取绿原酸标品1.5mg,用50%乙醇定容于25mL容量瓶中,摇匀配置成标准溶液。精确吸取绿原酸标液0mL,1mL,2mL,3mL,4mL,5mL置于10mL容量瓶中,稀释至刻度,采用紫外分光光度计在325nm下测定吸光度绘制标准曲线,测定葵花籽绿原酸含量。
实验例1葵花籽蛋白的制备
将葵花籽通过贝尔斯顿ZYJ-9028全自动榨油机采用冷榨法脱油,脱油前后油脂含量由47.36%降为23.09%,而后采用超声波辅助醇提法脱除绿原酸,所述超声波辅助醇提具体为:将脱油后葵花籽置于体积分数60%的乙醇中,料液比1:13,于40℃下超声提取30min,超声功率150W,真空抽滤,而后将滤渣进行真空干燥,即可得到葵花籽粉。经检测,超声波辅助醇提前后的绿原酸含量由2.04%降低至0.3%。
实验例2动物饲养与分组
选取6周龄雄性C57BL/6J小鼠(SPF级,购于常州卡文斯实验动物有限公司)。小鼠自由进水进食,预饲养1周后,按体重将小鼠随机分为6组,每组10只,即正常对照组(CON)、模型组(MOD)、葵花籽组(SFS)、葵花籽组(脱除绿原酸,RSFS)、乳清蛋白组(WPC)、鱼胶原蛋白组(FCP),喂养处理4周,所有动物自由饮水,第4周末收集粪便、尿液。正常对照组和模型组喂食动物中心提供的普通日粮饲料,其余各组饲料配方如下。
CON组:每1000g含有大豆蛋白粉175g(提供蛋白140g),蔗糖100.3g,玉米淀粉506.8g,葵花籽油85g,矿物质添加剂(表1所示,根据AIN-93M配制)27.3g,微晶纤维素50g,胆碱2.3g,ω-3脂肪酸0.5g,复合维生素10g(其中含有维生素A8mg、维生素B1和B2各6mg,维生素B6 7mg,维生素B12 10ug,叶酸2mg)。
MOD组的饲料配方同CON组。
SFS组:在CON组的基础上,将175g大豆蛋白粉替换为脱油处理的葵花籽粉367g(提供蛋白140g),将玉米淀粉含量调整为439.4g,不添加葵花籽油,纤维素调整为31.7g;其中,脱油处理的葵花籽粉是经过如下处理:将葵花籽通过贝尔斯顿ZYJ-9028全自动榨油机采用冷榨法脱油,脱油前后油脂含量由47.36%降为23.09%,再收集渣相进行真空干燥,得到葵花籽粉,其绿原酸含量为2.04%。
RSFS组的饲料配方同SFS组,区别在于,将脱油处理的葵花籽粉替换为实施例1的方法制备的葵花籽粉。
WPC组:在CON组的基础上,将大豆蛋白粉替换为乳清蛋白粉,乳清蛋白粉211g(提供蛋白140g),将玉米淀粉含量调整为474.1g。
FCP组:在CON组的基础上,将大豆蛋白粉替换为鱼胶原蛋白粉,鱼胶原蛋白粉164g(提供蛋白140g)将玉米淀粉含量调整为511g。
表1矿物质混合物(AIN-93M-MX)
模型构建:除CON组外,其余各组小鼠单笼饲养,参照慢性不可预测的轻度压力诱导抑郁模型(CUMS)对小鼠进行抑郁诱导,以每天2次的频率交替应激小鼠28d,结束后收集尿液、粪便1次。诱导结束后对小鼠进行糖水偏好测试和行为学评价。应激处理如下:
第1天:笼具45°倾斜2h;夹尾3min;
第2天:于无垫料的笼具中4h;同笼3h(5只)
第3天:笼具45°倾斜2h;禁水禁食12h
第4天:大鼠垫料3h;空笼具加水0.8cm淹没4h;
第5天:夹尾3min;同笼3h(5只),
第6天:禁水,禁食12h;大鼠垫料3h;
第7天:空笼具加水淹没4h;笼具45°倾斜2h;
第2、3、4周同上
实施例3小鼠行为学评价
(1)体重记录
实验过程中每周称量1次。如图2所示在造模开始前(第4周)各组小鼠体重均呈增长趋势,体重基本无显著性差异,造模第1周,除CON组外,其余各组体重出现下降趋势,突然对其施加CUMS模型,可能造成饮食不适而出现体重下降趋势。从第5周开始除FCP组体重呈现下降趋势外,各组小鼠体重开始恢复增长趋势,与MOD组相比,SFS和RSFS组体重呈明显增长趋势(p<0.05),SFS组体重由21.61(±0.48)g增长至27.81(±0.57)g;RSFS组由20.88(±0.68)g增长至27.48(±1.34)g;MOD体重增长减缓,由20.16(±0.69)g增长至25.52(±1.30)g;CON整个期间呈现增长趋势,由20.34(±0.78)g增长至26.78(±0.88)g,。我们发现喂食脱脂葵花籽和喂食脱脂脱除绿原酸葵花籽的小鼠体重增加更为明显,因此葵花籽蛋白有改善小鼠抑郁行为的活性,可有效缓解抑郁情绪。
(2)糖水偏好实验
糖水偏爱实验是评价快感缺失的一种方法,分为训练期和测试期。训练期:给予小鼠一瓶1%蔗糖水和一瓶纯水48h,中间交换水瓶位置,让小鼠适应饮用糖水。测试期:小鼠禁水禁食12h后进行12h的糖水偏好测试,测试前后分别称量每个水瓶的重量,并计算糖水偏爱指数(糖水偏爱指数=糖水消耗量/总液体消耗量×100%)。造模结束后第2天进行糖水偏爱实验。
如表2和图3所示,与CON组对比,MOD组小鼠的糖水偏好率呈现明显下降趋势(p<0.05);与MOD组对比,SFS和RSFS组对糖水的偏好率明显提高(分别提高18.1%,25.4%左右),其中以RSFS组最为显著(p<0.05),比阳性对照WPC组和CON组提升更为明显(p<0.05)。因此表明葵花籽明显提升小鼠对糖水的偏好率,增加小鼠对糖水的喜好和快感,对小鼠的抑郁症状具有明显的改善作用。
表2葵花籽对小鼠糖水偏好率的影响
结果为平均值±标准偏差,不同上标表示差异显著(p<0.05)
(3)旷场实验
旷场实验(Open field test,OFT)又称敞箱实验,是评价实验动物在新环境中自发活动的一种方法。主要是为了评价葵花籽蛋白是否对小鼠有副作用,比如影响小鼠的自发活动或者引起小鼠焦虑样行为。在一个黑暗的房间里,放置一个(40×40×30cm)的实验箱。实验箱由黑色透明有机玻璃组成,在实验箱的上方装有与电脑连接的摄像机,跟踪和记录小鼠在实验中的实时图像以获得行为数据。测试区分为16个正方形(10×10cm)。位于中心区域的四个正方形被定义为中心区。为了评估小鼠的自发活动,将每只小鼠放在盒子的中心并允许其自由探索30分钟。
如表3所示,MOD、FCP组和CON、WPC组小鼠在水平运动总路程无显著性差异,但SFS和RSFS组比MOD组小鼠运动总路程明显增加(p<0.05);MOD组小鼠进入中央区域时间、进入中央区域次数比CON组明显减少,进入中央区域路程与正常组无差异性。与SFS和RSFS组相比,中央区域时间、中央区域路程、进入中央区域次数均显著减少(p<0.05)。结果表明喂养葵花籽后的小鼠自主活动性增加,相比于模型组,焦虑状态得到了有效缓解,对空间的探索性明显增强,且缓解效果比阳性对照乳清蛋白效果较为显著,脱除绿原酸的葵花籽和葵花籽二者无显著性差异。
表3葵花籽对小鼠旷场实验活动的影响
结果为平均值±标准偏差,同列不同上标表示差异显著(p<0.05)
(4)悬尾实验
悬尾实验(Tail suspension test,TST)是利用小鼠悬尾后企图逃脱但又无法逃脱,从而放弃挣扎,进入抑郁不动状态的一种行为。将小鼠倒置,用胶布将小鼠尾巴(距尾尖1cm)粘贴于固定装置上,头部距桌面约20cm,使小鼠前后左右均无攀抓的地方,每两只小鼠间用挡板隔开其视线,以防止相互干扰,观察每只动物6min内后4min的累计不动时间(不动指标为小鼠除呼吸外所有肢体均不动)。
(5)强迫游泳实验
强迫游泳(forced swimming test,FST)是一种行为绝望实验法,通过将动物置于局限的环境中,动物拼命挣扎逃跑又无法逃脱,从而提供了一个无可回避的压迫环境,一段时间后,动物即表现出典型的“不动状态”。将小鼠放于高25cm,直径18cm,水深12cm,水温25℃的烧杯中,将其放入水中6min,记录后4min内累计不动时间。不动是指小鼠在水中停止挣扎,或呈漂浮状态,仅有细小的肢体运动以保持头部浮在水面,身体没有全身运动。
表4葵花籽对小鼠悬尾和强迫游泳实验活动的影响
结果为平均值±标准偏差,同列不同上标表示差异显著(p<0.05)
悬尾实验和强迫游泳实验是评价抑郁行为的经典实验,如图4(a)、(b)所示,可以看出在TST和FST实验中,与CON组相比,MOD组小鼠静止不动时间均显著增加(p<0.05)(32.4%,74.3%),与MOD组相比,SFS和RSFS组静止时间显著减少(p<0.05),SFS组不动时间分别减少28.2%、35.3%;RSFS组不动时间分别减少40.5%、32.6%。结果表明模型组小鼠在局限的环境中表现出明显的行为绝望状态,“不动时间”明显增加,而喂食葵花籽和脱除绿原酸的葵花籽的小鼠不动时间则明显降低,表现出类似于乳清蛋白抗抑郁的效果,表明葵花籽可有效缓解焦虑状态。
(6)高架十字迷宫实验
高架十字迷宫实验(Elevated plus maze,EPM)是评价小鼠的焦虑状态的经典行为学实验。实验装置是由尺寸为50×5cm(长×宽)的两条开放臂和两条闭臂交叉组成的,其中闭臂由高30cm的不透明墙封闭起来,中央区域尺寸是5×5cm,没有墙封闭,整个装置离地面的高度是45cm。其原理是小鼠天性嗜暗,倾向于待在封闭臂中,但是对新物体的好奇又会促使它进入开放臂,两者之间发生探究与回避的冲突行为,小鼠产生焦虑。而悬空的高架又会让小鼠产生恐惧不安的心理。因此,通过比较小鼠进入开放臂的次数及停留时间就可以评价小鼠的焦虑状态。
由表5可知,CON、SFS、RSFS和WPC组进入总次数与MOD组相比较不存在显著性差异,但是SFS和RSFS组进入总次数比MOD组多,且进入开放臂的次数和停留时间、进入时间百分比(OT%)与MOD组相比存在显著性差异,表现更好。由此可知葵花籽可有效改善小鼠的抑郁症状,且脱除绿原酸的葵花籽效果更加显著。
表5葵花籽对小鼠高架十字迷宫实验活动的影响
结果为平均值±标准偏差,同列不同上标表示差异显著(p<0.05)
实施例4生化指标测定
(1)海马神经递质的测定
海马组织中血清素(5-HT)、多巴胺(DA)和去甲肾上腺素(NE)含量严格按照ELISA试剂盒说明书进行操作。
如图5所示,可以发现与CON组相比,MOD组5-HT、DA和NE含量显著降低(p<0.05)(分别降低19.03%、35.46%、35.18%左右)。与CON组相比,SFS组5-HT、DA和NE含量分别提高了36.68%、20.21%和70.48%;RSFS组5-HT、NE含量分别提高22.61%、10.64%,DA含量变化不大,表现比MOD好。虽然二者无显著性差异且但SFS组比RSFS组含量更高一点。表明葵花籽可增加脑内愉悦性神经递质浓度,缓解小鼠快感缺失状态,增加快感,有效缓解小鼠抑郁焦虑情绪。
综合实施例3~4的评价结果可以看出所选葵花籽可明显增加小鼠体重,且比阳性对照乳清蛋白效果较好;明显提升小鼠对糖水的偏好率,增加小鼠对糖水的喜好和快感,具有改善小鼠抑郁行为的活性,可有效缓解抑郁情绪。
旷场实验显示葵花籽可使小鼠自主活动性增强,相比于模型组,焦虑状态得到了有效缓解,对空间的探索性明显增强,且缓解效果比阳性对照乳清蛋白效果较为显著;可明显缩短悬尾实验和强迫游泳实验中小鼠的静止不动时间,表现出类似于乳清蛋白抗抑郁的效果;高架十字迷宫结果显示在较大环境压力下,葵花籽可有效改善小鼠焦虑行为,缓解其抑郁情绪。
葵花籽能够增加脑内愉悦性神经递质浓度,缓解小鼠快感缺失状态,增加快感。因而葵花籽可有效缓解抑郁行为能够发挥类似于乳清蛋白的抗抑郁作用,具有缓解抑郁的活性,可有效治疗抑郁症,葵花籽比脱除绿原酸后效果表现更好一点。
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。
Claims (10)
1.葵花籽或含葵花籽的组合物在辅助治疗、缓解或改善抑郁情绪,或制备治疗抑郁症的药物中的应用,其特征在于,所述葵花籽中的色氨酸含量≥1.0g/100g葵花籽蛋白。
2.根据权利要求1所述的应用,其特征在于,所述组合物中含有葵花籽30-500g,葡萄糖25~150mg,ω-3脂肪酸200~1000mg和复合维生素。
3.根据权利要求1或2所述的应用,其特征在于,所述葵花籽的摄入量不少于1.5g葵花籽/kg体重,或所述葵花籽组合物的摄入量不少于3g葵花籽组合物/kg体重。
4.一种葵花籽蛋白,其特征在于,将葵花籽先后经过脱脂、脱绿原酸处理;所述脱脂处理是经榨油机脱油至油脂含量≤24%;所述脱绿原酸的过程是:将葵花籽置于体积分数50%-60%的乙醇中,料液比1:(10~14),于35~50℃下超声提取25~35min,超声功率140~160W,再进行过滤,干燥。
5.根据权利要求4所述的葵花籽蛋白,其特征在于,所述干燥为真空干燥。
6.根据权利要求4所述的葵花籽蛋白,其特征在于,色氨酸含量≥1.0g/100g葵花籽蛋白。
7.含有权利要求4~6任一所述葵花籽蛋白的组合物。
8.根据权利要求7所述的组合物,其特征在于,含有葡萄糖25~150mg,叶酸0.4~2mg,ω-3脂肪酸200-1000mg和复合维生素。
9.根据权利要求8所述的组合物,其特征在于,所述复合维生素包括维生素A、维生素B1,维生素B2,维生素B6,维生素B12和叶酸。
10.权利要求4~6任一所述的葵花籽蛋白或权利要求7~9任一所述的组合物在制备预防、治疗、缓解或改善抑郁情绪的食品、保健品或食品添加剂中的应用;所述葵花籽满足:色氨酸含量≥1.0g/100g葵花籽蛋白的要求。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010005574.3A CN111053798B (zh) | 2020-01-03 | 2020-01-03 | 一种富含愉悦激素前体的葵花籽组合物及抗抑郁应用 |
PCT/CN2020/122042 WO2021135520A1 (zh) | 2020-01-03 | 2020-10-20 | 一种富含愉悦激素前体的葵花籽组合物及抗抑郁应用 |
EP20900726.9A EP3884954A4 (en) | 2020-01-03 | 2020-10-20 | SUNFLOWER SEED COMPOSITION RICH IN RELAXATION HORMONE PRECURSORS AND USE AS AN ANTIDEPRESSANT THEREOF |
US17/420,366 US20220339229A1 (en) | 2020-01-03 | 2020-10-20 | Sunflower seed composition rich in pleasant prohormone and anti-depression application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010005574.3A CN111053798B (zh) | 2020-01-03 | 2020-01-03 | 一种富含愉悦激素前体的葵花籽组合物及抗抑郁应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111053798A true CN111053798A (zh) | 2020-04-24 |
CN111053798B CN111053798B (zh) | 2022-04-08 |
Family
ID=70304893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010005574.3A Active CN111053798B (zh) | 2020-01-03 | 2020-01-03 | 一种富含愉悦激素前体的葵花籽组合物及抗抑郁应用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220339229A1 (zh) |
EP (1) | EP3884954A4 (zh) |
CN (1) | CN111053798B (zh) |
WO (1) | WO2021135520A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021135520A1 (zh) * | 2020-01-03 | 2021-07-08 | 洽洽食品股份有限公司 | 一种富含愉悦激素前体的葵花籽组合物及抗抑郁应用 |
CN115721009A (zh) * | 2021-08-25 | 2023-03-03 | 中国科学院上海营养与健康研究所 | 缓解抑郁的方法、组合物及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6503543B1 (en) * | 2000-05-26 | 2003-01-07 | Craig J. Hudson | Tryptophan source from plants and uses therefor |
CA2410966C (en) * | 2002-11-01 | 2005-11-22 | Craig J. Hudson | Sexual desire and performance enhancement with protein-bound tryptophan |
PL3295803T3 (pl) * | 2009-02-27 | 2021-07-12 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Preparaty białkowe z nasion słonecznika i ich wytwarzanie |
CN107823473A (zh) * | 2017-11-23 | 2018-03-23 | 安徽东盛友邦制药有限公司 | 一种脑力静中健脑益智有效成分的超临界提取工艺 |
CN111053798B (zh) * | 2020-01-03 | 2022-04-08 | 洽洽食品股份有限公司 | 一种富含愉悦激素前体的葵花籽组合物及抗抑郁应用 |
-
2020
- 2020-01-03 CN CN202010005574.3A patent/CN111053798B/zh active Active
- 2020-10-20 US US17/420,366 patent/US20220339229A1/en active Pending
- 2020-10-20 WO PCT/CN2020/122042 patent/WO2021135520A1/zh unknown
- 2020-10-20 EP EP20900726.9A patent/EP3884954A4/en active Pending
Non-Patent Citations (2)
Title |
---|
南朝君: "《食疗营养与烹调》", 31 January 2014, 中国医药科技出版社 * |
阳元娥等: "超声提取葵粕绿原酸研究", 《声学技术》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021135520A1 (zh) * | 2020-01-03 | 2021-07-08 | 洽洽食品股份有限公司 | 一种富含愉悦激素前体的葵花籽组合物及抗抑郁应用 |
CN115721009A (zh) * | 2021-08-25 | 2023-03-03 | 中国科学院上海营养与健康研究所 | 缓解抑郁的方法、组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2021135520A1 (zh) | 2021-07-08 |
US20220339229A1 (en) | 2022-10-27 |
EP3884954A4 (en) | 2022-04-13 |
EP3884954A1 (en) | 2021-09-29 |
CN111053798B (zh) | 2022-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017124921A9 (zh) | 一种核桃低聚肽粉及其制备方法和用途 | |
KR101870846B1 (ko) | 다기능성 조성물 및 이의 제조 방법과 용도 | |
CN111053798B (zh) | 一种富含愉悦激素前体的葵花籽组合物及抗抑郁应用 | |
US5807554A (en) | Herbal formulations with nacre | |
CN114947141A (zh) | 一种具有皮肤美容功效的组合物及其用途 | |
CN106722934B (zh) | 一种含地龙、沙蚕含肽提取物的抗衰保健食品 | |
CN112315995A (zh) | 一种含有元宝枫籽油的组合物及其制备方法 | |
CN110038119A (zh) | 一种具有降尿酸和抗疲劳作用的药物组合物 | |
CN103750094B (zh) | 雄蜂蛹保健膏及其制备方法 | |
KR101357078B1 (ko) | 굴 패각을 이용한 항염증 또는 골관절염 저해 효과를 갖는 분획물의 분리방법 | |
CN101208351A (zh) | 用于治疗非自体免疫性2型糖尿病和/或x综合征的化合物 | |
KR101689259B1 (ko) | 데커신 및/또는 데커시놀 안젤레이트 또는 데커신 및/또는 데커시놀 안젤레이트를 유효성분으로 하는 당귀추출물, 쌀눈 추출물, 무말랭이 추출물을 유효성분으로 포함하는 운동에 기한 피로 또는 스트레스의 예방 또는 회복용 조성물 | |
CN109965072A (zh) | 一种养护肝脏的压片糖果及其制备方法与应用 | |
CN105031419A (zh) | 一种具有解酒保肝作用的组合物及其制备方法 | |
KR102668450B1 (ko) | 청각 추출물 또는 이의 분획물을 유효성분으로 포함하는 숙취해소제 | |
CN101745042B (zh) | 一种具有解酒保肝作用的组合物及其制备方法 | |
CN101143203B (zh) | 一种具有护肝养胃功能的复方口服液 | |
CN109157548B (zh) | 一种具有抗疲劳和壮阳功能的组合物及制备方法 | |
CN103039977A (zh) | 一种同时具有提高免疫力和耐缺氧作用的保健食品及其制备方法 | |
CN109821004B (zh) | 一种具有解酒护肝功能的组合物及其制备方法 | |
CN113713049A (zh) | 用于辅助抗疲劳的中药复方制剂 | |
CN101530209A (zh) | 一种调节血脂及护肝的保健食品及其制备方法 | |
CN112641100A (zh) | 一种含叶酸的抗抑郁冲剂 | |
CN100391476C (zh) | 一种延缓衰老、提高免疫力的药物组合物及其制备方法 | |
CN101940317B (zh) | 一种提高人体免疫力的保健食品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20201014 Address after: 230601 Lianhua Road, Hefei economic and Technological Development Zone, Anhui Applicant after: QIAQIA FOOD Co.,Ltd. Address before: No. 1800 road 214000 Jiangsu Lihu Binhu District City of Wuxi Province Applicant before: Jiangnan University Applicant before: QIAQIA FOOD Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |